Loading insider details...
Beta
Latest Form 4 (Aug 28, 2026): Exercise/Conversion of 11,148 ARQT shares, $83.7K.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 28, 2026 | Arcutis Biotherapeutics, Inc. (ARQT) | Exercise/Conversion | 11,148 | $83.7K |
| Aug 24, 2026 | Arcutis Biotherapeutics, Inc. (ARQT) | Exercise/Conversion | 1,072 | $8.1K |
| Jun 10, 2026 | Arcutis Biotherapeutics, Inc. (ARQT) | Grant/Award | 5,778 | n/a |
| Jun 17, 2025 | Arcutis Biotherapeutics, Inc. (ARQT) | Grant/Award | 7,609 | n/a |
| Mar 3, 2025 | Phathom Pharmaceuticals, Inc. (PHAT) | Grant/Award | 342,500 | n/a |
| Jan 23, 2025 | Phathom Pharmaceuticals, Inc. (PHAT) | Sale | 19,109 | $125.9K |
| Nov 13, 2024 | Arcutis Biotherapeutics, Inc. (ARQT) | Sale | 8,687 | $94.2K |
| Jul 17, 2024 | Phathom Pharmaceuticals, Inc. (PHAT) | Sale | 33,848 | $396.7K |
| Jun 18, 2024 | Arcutis Biotherapeutics, Inc. (ARQT) | Grant/Award | 10,139 | n/a |
| Mar 26, 2024 | Phathom Pharmaceuticals, Inc. (PHAT) | Sale | 16,851 | $153.5K |